Ardent Health, Inc. (ARDT)

NYSE: ARDT · USD

$11.9

+0.03 (+0.3%)· Recorded snapshot

Market cap	1.7B
Revenue (ttm)	6.4B
Net income (ttm)	78.2M
EPS (ttm)	$0.55
Shares out	141M
P/E (trailing)	21.5x
P/E (forward)	10.4x
Volume	306,878
Beta	0.72

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 6.4B
Net income (ttm): 78.2M
EPS (ttm): $0.55
P/E (trailing): 21.5x
P/E (forward): 10.4x
Market cap: 1.7B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E10.4

P25 n/aP50 n/aP75 n/a

Trailing P/E21.5

P25 n/aP50 n/aP75 n/a

ROE10

P25 n/aP50 n/aP75 n/a

ROIC6.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ARDT indicators

Market & fundamental data

Available fields

242

Groups with data

Currency

USD

Showing 242 of 242 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001756655
Company name	Ardent Health, Inc.
Country	United States
Country code	US
CUSIP number	03980N107
Earnings date	2026-11-04
Earnings time	amc
Employees	25,200
Employees change	300
Employees growth	1.2%
Enterprise value	$3.2B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2001
In index	RUSSELL2000
Industry	Medical Care Facilities
IPO date	2024-07-18
Is primary listing	Yes
Is SPAC	No
ISIN number	US03980N1072
Last 10-K release date	2026-03-16
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.7B
Market cap category	Small-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$11.86
Price currency	USD
Sector	Healthcare
SIC code	8062
Stock price date	2026-10-28
Symbol	ARDT
U.S. state	Tennessee
Website	https://www.ardenthealth.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	6.7x
Average P/E ratio (3Y)	12.78x
Earnings yield	4.66%
EV/Earnings	41.27x
EV/EBIT	12.52x
EV/EBITDA	7.64x
EV/FCF	10.59x
EV/Sales	0.5x
FCF / EV yield	9.44%
FCF yield	18.08%
Forward EV/Sales	0.49x
Forward P/E	10.35x
Forward P/S	0.26x
Graham number	10.87317
Graham upside	-9.01%
Industry forward P/E	14.95x
Industry P/E	18.37x
Lynch fair value	$2.76
Lynch upside	-76.9%
P/(FCF - SBC) ratio	6.26x
P/(OCF - SBC) ratio	3.52x
P/B ratio	1.24x
P/E ratio	21.48x
P/FCF ratio	5.53x
P/OCF ratio	3.28x
P/S ratio	0.26x
PEG ratio	2.77x
Price / tangible book value	4.39x
Price/EBITDA ratio	3.99x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	4.03%
EBITDA margin	6.59%
Effective tax rate	18.91%
FCF margin	4.76%
Gross margin	58.38%
Operating margin	4.03%
Pretax margin	3.25%
Profit margin	1.22%
Profit per employee	$3,104
Profitable quarters	3
Profitable years	5
Revenue per employee	$254,204
ROA	3.13%
ROCE	5.99%
ROE	9.96%
ROIC	6.25%
SBC / revenue	0.56%
Tax / revenue	0.61%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-69.6%
EPS growth (Q)	-77.05%
EPS growth (QoQ)	-57.4%
EPS growth years	0
FCF growth	181.84%
FCF growth (Q)	121.7%
FCF growth 3Y	237.8%
FCF growth 5Y	81.74%
Gross profit growth	4.47%
Gross profit growth (Q)	-2.83%
Gross profit growth 3Y	13.23%
Gross profit growth 5Y	30.16%
Net income growth	-69.31%
Net income growth (Q)	-76.84%
Net income growth (QoQ)	-57.59%
Net income growth 3Y	-20.26%
Net income growth years	0
OCF growth	70.32%
OCF growth (Q)	67.45%
OCF growth 3Y	51.84%
OCF growth 5Y	46.89%
Operating income growth	-40.35%
Operating income growth (Q)	-59.37%
Operating income growth 3Y	-5.25%
Operating income growth 5Y	14.24%
Revenue growth	3.35%
Revenue growth (Q)	-1.4%
Revenue growth (QoQ)	1.27%
Revenue growth 3Y	9.57%
Revenue growth 5Y	33.52%
Revenue growth years	4

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-209.6M
Depreciation and amortization	$164.5M
EBIT	$257.9M
EBITDA	$422.4M
EPS	$0.55
FCF per share	$2.16
Financing cash flow	$-118.5M
Free cash flow	$304.8M
Free cash flow minus SBC	$269.1M
Gross profit	$3.7B
Income taxes	$39.3M
Investing cash flow	$-211.9M
Net borrowing	$-7.1M
Net cash flow	$183.8M
Net income	$78.2M
Operating cash flow minus SBC	$478.7M
Operating income	$257.9M
Revenue	$6.4B
Stock-based compensation	$35.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.03
Book value per share	$9.52
Debt / EBITDA	3.31
Debt / equity	1.3
Debt / FCF	7.44
Goodwill	$879.3M
Interest coverage	5.05
Long-term assets	$3.2B
Long-term liabilities	$2.6B
Net cash (debt)	$-1.5B
Net cash / market cap	-91.53%
Net debt / EBITDA	3.65
Net debt / equity	0.89
Net debt / FCF	5.06
Piotroski F-Score	6
Property, plant and equipment	$2.1B
Shareholders' equity	$1.7B
Tangible book value	$383.6M
Tangible book value per share	$2.70
Total assets	$5.3B
Total cash	$724.5M
Total debt	$2.3B
Total liabilities	$3.5B
WACC	4.54%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.24
Current assets	$2.1B
Current liabilities	$976.3M
Current ratio	2.1
Inventory turnover	22.74
Net working capital	$382.8M
Quick ratio	1.49
Working capital	$1.1B
Working capital turnover	6.18

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.33%
Dividend yield	0%
Shareholder yield	-1.33%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$10.26
1D price change	0.25%
1M price change	12.86%
1M total return	12.86%
1W price change	-1.86%
1W total return	-1.86%
1Y price change	-21.43%
1Y return CAGR	-21.45%
1Y total return	-21.43%
20-day SMA	$11.54
200-day SMA	$9.95
3M price change	8.63%
3M total return	8.63%
50-day SMA	$11.10
50-day SMA vs 200-day SMA	50over200
52-week high	$15.48
52-week high date	2025-10-29
52-week low	$7.71
52-week low date	2026-06-03
6M price change	18.48%
6M total return	18.48%
All-time high	$20.72
All-time high date	2024-10-16
All-time low	$7.71
All-time low date	2026-06-03
Average true range (ATR)	$0.41
Average volume	457.7K
Beta (1Y)	0.74
Beta (2Y)	0.56
Beta (5Y)	0.72
Change from 52-week high	-23.39%
Change from 52-week low	53.83%
Change from all-time high	-42.59%
Change from all-time low	54.28%
Change from open	-1.5%
Day's gap	1.78%
Dollar volume	$3.6M
High price	$12.05
Low price	$11.81
Monthly RSI	47.47
Open price	$12.04
Position in 52-week range	20.83%
Previous close	$11.83
Price vs 150-day SMA	15.89%
Price vs 20-day SMA	3.08%
Price vs 200-day SMA	19.56%
Price vs 50-day SMA	7.17%
Relative volume	0.67
Return from IPO open	-20.33%
Return from IPO price	-25.31%
RSI	57.54
Sharpe ratio	-0.22
Sortino ratio	-0.17
Volume	306.9K
Weekly RSI	61.6
YTD price change	34.71%
YTD total return	34.71%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	21.8M
Float percentage	15.43%
Shares change (QoQ)	0.9%
Shares change (YoY)	1.33%
Shares held by insiders	1.72%
Shares held by institutions	22.35%
Shares outstanding	141M
Short % of float	21.29%
Short % of shares	3.28%
Short ratio	10.6 days

Deeper analysis on ARDT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ARDT report

Is a complete ARDT research report available?

No complete published report is available for Ardent Health, Inc. (ARDT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Ardent Health, Inc. (ARDT)

Price

Financial snapshot

Fair-value bridge

Latest news · ARDT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ARDT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ARDT

Frequently asked questions